TMO — Thermo Fisher Scientific Inc.

Momentum and coverage are both strongly positive. Q3 2026 (reported 2026-10-21) beat on revenue ($12.14B, +9% YoY, ~$190M above consensus) and adjusted EPS ($6.68, +15%, $0.28 beat), and management raised full-year guidance. Sell-side responded with a wave of target hikes — TD Cowen to $760, Barclays and Morgan Stanley to $750/$730, and a UBS upgrade to Buy at $730 — leaving a 36-buy/7-hold/0-sell consensus. The stock is up 26.75% over three months and 29.82% over six, sitting near its 52-week high. The main offset is persistent insider distribution (~$44-158M sold over the past year, no open-market buys).

This is a clear inflection, not a blip. Revenue growth troughed at +0.2% YoY in Q1 2025, then +3.0% (Q2 2025), +4.9% (Q3 2025), +7.2% (Q4 2025), +6.2% (Q1 2026), +10.5% (Q2 2026) and +9.1% (Q3 2026) — a steady re-acceleration that also shows up sequentially ($11.0B Q1 → $11.99B Q2 → $12.14B Q3 2026). GAAP operating margin has held in a ~17-18.6% band (18.65% in Q3 2026) while adjusted operating margin expanded to 24.5%. GAAP diluted EPS rose 8.7% YoY in Q3 2026 ($4.64 vs $4.27) and adjusted EPS +15%; free cash flow rose to $2.113B from $1.835B a year earlier (+15%). Earnings quality is clean — the accruals ratio is -0.73% (cash running ahead of reported profit). The trend is accelerating out of a post-COVID/biotech-funding digestion trough.

Fairly valued to modestly rich. As of 2026-10-21 the trailing P/E was 36.26x versus a 5-year average of 32.65x, P/S 5.38x vs a 5.16x 5-year average, and PEG a steep 3.81 — all signaling the trailing multiple sits above its own history. The offset is forward math: on the $25.145 next-FY adjusted EPS estimate the forward P/E is ~27.4x, below both the trailing figure and its long-run average, because earnings are expected to grow into the multiple. Net read: full on trailing numbers, roughly fair-to-slightly-cheap on forward numbers, and not a value case.

The market has already re-priced the recovery, not anticipated the next leg. Between the trough and 2026-10-21 the stock gained ~27% in three months, moving from a defensive laggard to a momentum name as Q2/Q3 beats and guidance raises confirmed the organic-growth re-acceleration. At ~27x forward the price now assumes continued mid-to-high single-digit organic growth and low-teens adjusted EPS growth; the beat-and-raise supports that, but the multiple-expansion phase looks largely spent. Further upside needs sustained organic acceleration and margin leverage — not just a higher multiple on the same earnings. Conversely, a single soft quarter (China, biotech funding) would leave little valuation cushion.

As of 2026-10-21 the technicals are firm but not stretched. RSI (14) was 52.32 — neutral, neither overbought nor oversold despite the big run. The stock sat -0.54% below its 20-day SMA, +4.03% above the 50-day, and a strong +21.64% above the 200-day, i.e., a well-established uptrend that has recently paused (1-week -0.88%, 1-month +1.29%) after the three-month surge. It is consolidating just under the $704 high. There is no compelling timing edge right now; a pullback toward the 50-day (~$662) would be a cleaner entry than chasing, but the trend itself remains up.

• Biopharma funding recovery and stabilizing interest rates are thawing capital constraints for small biotech, reviving instrument demand and CRO/bioproduction orders.
• China and broader international recovery remain the key swing factor — softness there has repeatedly capped reported growth and is a persistent read-through risk.
• Healthcare/defensive sector rotation benefits TMO's low beta (0.878) in risk-off tapes, but can reverse quickly in risk-on rotations away from defensives.
• Pharma R&D budget trends and U.S. federal research funding (NIH) shape the instrument and consumables demand backdrop; policy cuts are a live tail risk.
• Tariffs, FX on a large global footprint, and supply-chain costs are ongoing margin swing factors.

• Commercial adoption of new products launched alongside Q3 results — the Orbitrap Isora isotope-ratio mass spectrometer, EMPAD G2 electron detector, and FDA-cleared EliA CTD 13 autoimmune test.
• Follow-through on the raised FY2026 guidance at the 2027-01-28 earnings report; sustained organic growth of 6%+ would validate the recovery.
• Continued biotech funding recovery and China stabilization feeding instrument and CRO demand.
• Further sell-side target revisions and re-rating toward the ~$750 high-end targets.

• Valuation risk: 36.26x trailing P/E and 3.81 PEG leave little cushion — any growth deceleration would compress the multiple sharply.
• China weakness or a stall in biotech funding recovery, which would undercut the organic-growth re-acceleration thesis.
• Persistent insider selling (~$44-158M over the past year with no open-market buys) is a mild negative signal on management's read of value.
• M&A-heavy history inflates goodwill and depresses reported ROIC (7.6%), raising impairment and integration risk.
• FX, tariffs, and product-mix shifts (bioproduction vs. instruments) pressure margins.

Thermo Fisher is a wide-moat life-sciences tools and services franchise in the early innings of a genuine cyclical recovery: organic growth re-accelerated from barely positive in early 2025 to ~6% in Q3 2026, margins are holding (adjusted op margin 24.5%), free cash flow is up double digits, and earnings are clean (negative accruals, -0.73%). The catch is price — at ~27x forward and 36x trailing earnings, up ~27% in three months, most of the recovery is already discounted, making this a great business at a full price rather than a bargain. Directional lean is Neutral: quality is not in doubt, but the risk/reward at this valuation is balanced rather than attractive.

Applied a ~28.4x forward P/E — a modest premium to the ~27.4x the stock traded at on 2026-10-21 and in line with TMO's historical range — to the next-FY adjusted EPS estimate of $25.145, reflecting re-accelerating organic growth and durable margins. This yields roughly $715, modestly above the $688.65 price on 2026-10-21 and consistent with the ~$690 median analyst target.